Zhifei Biological's tetanus vaccine clinical trial application accepted
Chongqing Zhifei Biological Products (SZSE:300122) announced that its subsidiary, Zhifei Green Bamboo Pharmaceutical, has received acceptance from the National Medical Products Administration for its clinical trial application for its adsorbed tetanus vaccine (CXSL2500250). Zhifei Green Bamboo can proceed with clinical trials if no objection is received within 60 days. The vaccine targets tetanus, a severe and potentially fatal disease caused by the bacterium Clostridium tetani. According to the company, the new vaccine uses column chromatography for antigen purification, resulting in higher purity and better batch consistency compared to traditional salt precipitation methods. There are currently 12 adsorbed tetanus vaccines on the market in China. Zhifei anticipates that a successful trial and product launch will enhance its adult vaccine offerings and strengthen its market competitiveness.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Chongqing Zhifei Biological Products publishes news
Free account required • Unsubscribe anytime